Estimating national, regional and provincial cost-effectiveness of introducing childhood 13-valent pneumococcal conjugate vaccination in China: a modelling analysisResearch in context
Summary: Background: Although 13-valent pneumococcal conjugate vaccine (PCV13) is available in China's private market, it has yet to be introduced into the National Immunization Programme (NIP) and is therefore not available to large parts of the population. This study aimed to estimate the cos...
Saved in:
Main Authors: | Xiaozhen Lai (Author), Cristina Garcia (Author), Dan Wu (Author), Maria Deloria Knoll (Author), Haijun Zhang (Author), Tingting Xu (Author), Rize Jing (Author), Zundong Yin (Author), Brian Wahl (Author), Hai Fang (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012) -
National, regional, and provincial disease burden attributed to Streptococcus pneumoniae and Haemophilus influenzae type b in children in China: Modelled estimates for 2010-17
by: Xiaozhen Lai, et al.
Published: (2022) -
13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017) -
Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021) -
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019)